Q3 Earnings Estimate for Atyr PHARMA Issued By HC Wainwright

Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Research analysts at HC Wainwright cut their Q3 2025 earnings estimates for shares of Atyr PHARMA in a note issued to investors on Thursday, May 8th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.19) per share for the quarter, down from their prior estimate of ($0.18). HC Wainwright has a "Buy" rating and a $35.00 price objective on the stock. The consensus estimate for Atyr PHARMA's current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Atyr PHARMA's FY2025 earnings at ($0.74) EPS, FY2026 earnings at ($0.67) EPS, FY2027 earnings at $0.38 EPS and FY2028 earnings at $0.49 EPS.

Other equities analysts have also recently issued reports about the stock. Leerink Partners initiated coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price target on the stock. Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $18.60.

Atyr PHARMA Trading Up 6.2%

ATYR traded up $0.19 during trading on Monday, reaching $3.19. 634,273 shares of the company's stock were exchanged, compared to its average volume of 917,143. The company's fifty day moving average price is $3.26 and its 200-day moving average price is $3.40. The firm has a market capitalization of $283.48 million, a PE ratio of -3.41 and a beta of 0.79. Atyr PHARMA has a fifty-two week low of $1.42 and a fifty-two week high of $4.66. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02.

Hedge Funds Weigh In On Atyr PHARMA

Large investors have recently modified their holdings of the business. Group One Trading LLC acquired a new position in shares of Atyr PHARMA during the 4th quarter worth about $26,000. Alterna Wealth Management Inc. acquired a new position in shares of Atyr PHARMA during the 4th quarter worth about $36,000. Victory Capital Management Inc. acquired a new position in shares of Atyr PHARMA during the 4th quarter worth about $37,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Atyr PHARMA during the 1st quarter worth about $38,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Atyr PHARMA during the 4th quarter worth about $39,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.